Pauling.AI
Category: AI in Biotech / Drug Discovery
An autonomous AI agent platform that automates computational drug discovery, going from a protein target to validated drug molecules in days. Pauling.AI was founded in 2024. The company is led by Javier Tordable. Based in Boston, MA, USA. Team size: 1-10. Latest round: Pre-Seed. Key investors include Flex Capital, Illium Venture Capital, angel investors.
- Founded
- 2024
- Headquarters
- Boston, MA, USA
- Team size
- 1-10
Value proposition
Pauling.AI's AI agent orchestrates 15+ computational chemistry pipelines (molecular docking, MD simulations via GROMACS, ADMET prediction, and latest AI models like Boltz and DiffDock) end-to-end, eliminating the need for computational chemistry expertise and compressing early-stage drug discovery timelines from years to days.
Products and solutions
Autochem platform: conversational AI agent for target-to-molecule workflow, receptor prep/protonation, large-scale molecular docking, AI structure/interaction models (Boltz, DiffDock), molecular dynamics & binding affinity (GROMACS, MM-PBSA), 80+ endpoint ADMET/safety profiling, automated QC (MolProbity, PoseBusters)
Unique value
Only platform combining autonomous AI agents, enterprise-scale cloud infrastructure, and integrated state-of-the-art AI models with traditional computational chemistry in one fully automated system (patent pending)
Target customer
Biotech and pharmaceutical companies, medicinal chemists, and drug discovery research teams
Industries served
Biotech / Pharmaceutical drug discovery
Technology advantage
Multi-LLM AI agents that autonomously select protocols and configure full computational pipelines (docking, MD, ADMET) at enterprise cloud scale, processing millions of compounds with fault-tolerant, restartable execution
How they differentiate
Focuses on full end-to-end workflow automation via a conversational AI agent rather than single-purpose models (like AlphaFold/Boltz alone) or expert-only complex tools (like Schrödinger), removing the need for computational chemistry expertise or CRO outsourcing
Main competitors
Chai Discovery, Isomorphic Labs, Iambic Therapeutics (also adjacent: insitro, Xaira Therapeutics)
Key partnerships
Backed/supported by Google for Startups, NVIDIA Inception, and Stripe Startups programs, Flex Capital (investor), Illium Venture Capital (investor), partnership with Auralis to jointly serve biotech customers, Plug and Play Tech Center (Seattle), UW CoMotion
Notable customers
Powerhouse Biology Inc, Solgate
Major milestones
Launched fully automated drug discovery AI agent for small molecules, presented at Plug and Play Seattle event, featured on AI Risk Reward podcast, speaker at Asia Bio Partnering Forum, partnership announcement with Auralis for biotech customer delivery
Market positioning
Autonomous 'scientist-as-a-service' platform positioned between point-solution AI models and full-service CROs, targeting speed and cost reduction in early-stage small-molecule drug discovery
Geographic focus
United States (Pacific Northwest / Boston biotech-AI ecosystem), competing globally with well-funded structure-foundation-model labs
Patents and IP
Patent pending (per company website; no public patent number disclosed)
About Javier Tordable
16 years at Google as Technical Director in the CTO Office, leading technical work across Search, Ads, Supply Chain and Cloud; also worked at Microsoft and interned at McKinsey; MIT (Executive Education), degrees in Computer Science Engineering and Mathematics, left a PhD in Mathematics to build technology companies.
Latest news about Pauling.AI
More AI in Biotech / Drug Discovery companies
Official website: https://www.pauling.ai
